You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥宣佈Dorzagliatin與二甲雙胍聯合用藥III期註冊臨牀研究24周核心研究取得正面結果
格隆匯 07-01 18:37

格隆匯7月1日丨華領醫藥(02552.HK)今日宣佈dorzagliatin(HMS5552)與二甲雙胍聯合用藥的關鍵III期註冊臨牀研究(HMM0302)在24周隨機、雙盲、安慰劑對照試驗中達到主要療效和安全性終點,該試驗在在二甲雙胍足量治療失效的中國2型糖尿病患者中展開,用以評估dorzagliatin的療效和安全性。

研究資料顯示,與對照組相比,dorzagliatin治療組的HbA1c應答率、HOMA2-β(β細胞功能指標)和HOMA2-IR(胰島素抵抗指標)、餐後兩小時血糖值和空腹血糖值均在統計學意義上顯著改善。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account